# Source: Halia Therapeutics Official Website and ASH 2025 Phase 2a Disclosure

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://haliatx.com
**Publisher:** Halia Therapeutics, Inc.
**Accessed:** 2026-06-18
**Updated:** 2026-06-18

## Summary

Halia Therapeutics' official website and its public disclosures around the American Society of Hematology (ASH) 2025 annual meeting, including a December 8, 2025 press release and the corresponding conference abstract describing Phase 2a results for ofirnoflast (HT-6184) in lower-risk MDS, plus the ClinicalTrials.gov record (NCT07052006).

## Useful Claims

- Halia Therapeutics is a Lehi, Utah clinical-stage biopharmaceutical company.
- Ofirnoflast (HT-6184) is described as a first-in-class oral allosteric NEK7 inhibitor targeting NLRP3 inflammasome activation.
- At ASH 2025, in a Stage 1 efficacy population of 18 evaluable patients, Halia reported a 72% hematologic improvement–erythroid (HI-E) response rate after at least 16 weeks, with high responses in ESA-refractory and ESA-intolerant patients and no treatment-related serious adverse events reported.
- The Phase 2a trial NCT07052006 was listed as active, not recruiting, with enrollment of 37 (actual) and a 2026 completion date.
- The disclosed pipeline includes an HT-6184 + semaglutide program for obesity/type 2 diabetes and a neuroinflammation candidate, HT-4253.
- The company's CEO/founder is David (Dave) Bearss.

## Reliability Notes

Press releases and conference abstracts are leads, not neutral evidence; they reflect the sponsor's framing of early-stage data. The ClinicalTrials.gov record is a reliable registry source for trial design, status, and enrollment. Financing details (amount raised, stage) are not established by these sources and need separate primary confirmation. Early efficacy signals do not predict success in larger confirmatory trials.

## Related Pages

- [Halia Therapeutics](halia-therapeutics.md)